Dr Reddy's Laboratories Share Price (DRREDDY)
Check the latest share price of Dr Reddy's Laboratories, along with the price target, peer comparison, quarterly results, recent news, expert analysis, shareholding pattern, and other key fundamentals to make informed investment decisions.
as on 04:01PM, 13 Jun 2025
NSE
Dr Reddy's Laboratories Stock Performance
Get live Dr Reddy's Laboratories share price, day's high and low, historical returns, and market stats.
Day's Low
Day's High
₹1,345Day's Price Range₹1,366.852 Week's Low
52 Week's High
₹1,02052-Week Price Range₹1,421.49
| Returns % | |
| 1 Month Return | + 11.68 % |
| 3 Month Return | + 18.41 % |
| 1 Year Return | + 11.95 % |
| 3 Year Return | + 58.02 % |
| 5 Year Return | + 69.79 % |
| Market Stats | |
| Previous Close | ₹1,362.70 |
| Open | ₹1,355.00 |
| Volume | 14.20L |
| Upper Circuit | ₹1,498.90 |
| Lower Circuit | ₹1,226.50 |
Dr Reddy's Laboratories Fundamentals & Key Indicators
Check Dr Reddy's Laboratories market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
₹1,13,702.42 Cr
Return on Equity (ROE)
19.42
PE Ratio (TTM)
20.07
Return on capital employed (ROCE)
25.4
Industry PE ratio
57.39
Beta (LTM)
0.64
P/B Ratio
4.22
Dividend Yield
0.65
PEG Ratio
23.78
Quarterly Earnings Growth YOY
21.14
EPS (TTM)
66.882
Sector
Pharmaceuticals
Book Value
339.97
Technical Analysis
Bullish
View Technical Analysis
How to invest in Dr Reddy's Laboratories?
Investing in Dr Reddy's Laboratories is simple. You can open a free INDstocks investment account on the INDmoney App. Search for Dr Reddy's Laboratories or DRREDDY on the app to check live prices of the stock and click on Buy or SIP. You can invest by selecting the number of shares or set up a fixed SIP to invest every month or week.
For example: You can buy 10 shares of Dr Reddy's Laboratories or start an SIP based on the market price on each investment date.
You can easily transfer money to your stock account via the INDmoney app and start investing in stocks like Dr Reddy's Laboratories with just a few clicks!
Dr Reddy's Laboratories Stock's Interest Amongst Investors
Dr Reddy's Laboratories Valuation
Track how Dr Reddy's Laboratories P/E has moved over time to understand its valuation trends.
Dr Reddy's Laboratories in the last 5 years
Lowest (3.37x)
October 27, 2019
Today (20.07x)
June 13, 2025
Industry (57.39x)
June 13, 2025
Highest (53.88x)
December 18, 2020
Today’s Price to Earnings Ratio: 20.07x
Dr Reddy's Laboratories Stock Recommendation
Get updated buy, sell, and hold recommendations by analysts on Dr Reddy's Laboratories.
based on 38 analysts
44.74%
Buy
21.05%
Hold
34.21%
Sell
44.74% of analysts recommend a 'HOLD' rating for Dr Reddy's Laboratories. Average target price of ₹1276.67
Source: S&P Global Market Intelligence
Dr Reddy's Laboratories Share Price Target
Get share price movements and forecasts by analysts on Dr Reddy's Laboratories.
Dr Reddy's Laboratories price forecast by 38 analysts
Downside of-6.30%
High
₹1575
Target
₹1276.67
Low
₹902
Dr Reddy's Laboratories target price ₹1276.67, a slight downside of -6.3% compared to current price of ₹1362.5. According to 38 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Dr Reddy's Laboratories revenue growth forecast
Expected growth rate Q1, FY2027:25.21%
Forecast
Actual
Including amortisation and stock based compensations
Dr Reddy's Laboratories EPS growth forecast
EPS estimate Q1, FY2027:
Forecast
Actual
Source: S&P Global Market Intelligence
Dr Reddy's Laboratories Financial Results
Get the annual and quarterly financial summary of Dr Reddy's Laboratories, including revenue, profit, loss and more.
Indices Featuring Dr Reddy's Laboratories Stock
Check stock indices that include Dr Reddy's Laboratories.
Dr Reddy's Laboratories Earnings and Dividends
View detailed summary of the earnings and dividend history of Dr Reddy's Laboratories.
Dr Reddys Laboratories Ltd Earnings Results
Dr Reddys Laboratories Ltd’s net profit jumped 21.64% since last year same period to ₹1,593.30Cr in the Q4 2024-2025. On a quarterly growth basis, Dr Reddys Laboratories Ltd has generated 12.7% jump in its net profits since last 3-months.
Read More about Earnings ResultsDr Reddys Laboratories Ltd Dividends May,2024
In the quarter ending March 2024, Dr Reddys Laboratories Ltd has declared dividend of ₹40 - translating a dividend yield of 5.87%.
Read More about Dividends
Dr Reddy's Laboratories Shareholding Pattern
View the shareholding pattern breakup of promoters, FIIs, DIIs, and retail investors in Dr Reddy's Laboratories.
| Investors | Holdings % | Quarterly Trend | 3M change |
|---|---|---|---|
| Promoter Holdings | 26.64% | 0.00 | |
| Foreign Institutions | 25.75% | 0.00 | |
| Mutual Funds | 12.88% | 0.00 | |
| Retail Investors | 10.15% | 0.00 | |
| Others | 24.57% | 0.00 |
Dr Reddy's Laboratories vs Peers
Compare market cap, revenue, PE, and other key metrics of Dr Reddy's Laboratories with its industry peers.
Company | Analyst View | Market Cap(in ₹ Cr) | 5 Year CAGR | Debt to Asset Ratio | Net Profit(in ₹ Cr) | Yearly Revenue(in ₹ Cr) |
|---|---|---|---|---|---|---|
| HOLD | 1,13,702.42 | 13.96% | 0.52 | 5,577 | 28,011 | |
| HOLD | 1,76,987.90 | 37.1% | 0.50 | 1,600 | 7,845 | |
| BUY | 1,10,074.44 | 32.82% | 0.67 | 1,656 | 10,727 | |
| BUY | 42,669.32 | -1.66% | 0.58 | 1,297 | 14,755 | |
| HOLD | 27,838.89 | -1.43% | 0.50 | 772 | 5,664 |
Dr Reddy's Laboratories News & Key Events
Latest news and events in one place to help you make informed investing decisions in Dr Reddy's Laboratories.
Dr. Reddy's Stock Shows Strength Amid Decline - 13 Jun, 2025
Dr. Reddy's Laboratories is experiencing notable trading activity, with a recent decline of 0.31%. Analysts suggest a buying opportunity if the stock dips to ₹1,340–1,345.Dr. Reddy's Faces Theft and Growth Prospects - 12 Jun, 2025
Nomura maintains a Buy rating on Dr. Reddy's Laboratories, setting a target price of ₹1,575. Meanwhile, eight individuals were arrested for stealing Semaglutide worth ₹2 crore from the company's warehouse, raising concerns about security and profitability beyond gRevlimid.Dr. Reddy's Engages Investors at CLSA Conference - 11 Jun, 2025
Dr. Reddy’s Laboratories will participate in the CLSA Investor Conference on June 18, 2025, in Hyderabad. The company maintains a Buy rating with a $17.40 price target, showcasing strong financial performance and positive momentum despite market challenges.Dr Reddys Continues Upward Trend with Fifth Gain - 09 Jun, 2025
Dr Reddys Laboratories Ltd has gained 0.07% today, marking its fifth consecutive session of increases. The stock is currently trading at Rs 1321.8, reflecting an 8.24% rise over the past year.Dr. Reddy's Laboratories: Navigating Future Opportunities - 07 Jun, 2025
Dr. Reddy's Laboratories is poised for growth despite the impending decline of gRevlimid sales. The company is investing in GLP-1RA generics and expanding its consumer health base through acquisitions and partnerships. While revenue growth is strong, challenges remain in regulatory approvals and competition. Long-term drivers are in place, but clarity on new investments is needed.Dr Reddy's Gains from Keytruda Biosimilar Collaboration - 05 Jun, 2025
Dr Reddy’s Laboratories announced a collaboration with Alvotech to develop a Keytruda biosimilar, boosting its oncology portfolio. Shares rose 4% following this news, alongside an upgrade from HSBC. LIC also increased its stake in the company to over 8.2%. This strategic partnership is expected to enhance Dr Reddy's market position significantly.Dr. Reddy's Explores US Manufacturing Opportunities - 03 Jun, 2025
Dr. Reddy's Laboratories is actively seeking partnerships and investment opportunities to enhance its manufacturing capabilities in the US, highlighting its strong financial position.Dr Reddy's Faces Legal Challenges and Tax Demand - 31 May, 2025
Dr Reddy's Laboratories faces a ₹2,396 crore tax demand and legal restrictions on selling semaglutide due to a patent infringement lawsuit by Novo Nordisk.Dr Reddy's Strategies Amid Revlimid Patent Expiry - 30 May, 2025
Dr Reddy's Laboratories plans to counter the impending revenue loss from Revlimid's patent expiry in January 2026 through new launches, biosimilars, and potential M&A. The company aims for sustained double-digit sales growth and is investing heavily in its pipeline, despite analysts' concerns about offsetting the Revlimid void. The CFO remains optimistic about maintaining strong financial performance.Dr Reddy's Laboratories Shows Marginal Gains - 28 May, 2025
On May 28, 2025, Dr Reddy's Laboratories shares rose by 0.37% to Rs 1247.80, reflecting bullish investor sentiment. The company continues to show steady financial performance.Dr Reddys Laboratories Stock Shows Positive Momentum - 21 May, 2025
Dr Reddys Laboratories stock experienced a rise of 1.18% to Rs 1,238.70, while also maintaining a steady price of Rs 1,224.20. The stock's inclusion in the NIFTY 50 index highlights its importance in the market, with a bullish sentiment noted in recent analyses.Dr. Reddy's Reports Strong Earnings and Investor Engagement - 20 May, 2025
Dr. Reddy's Laboratories reported a revenue increase to Rs 32,643.90 crore for FY 2025, with a net profit of Rs 5,703.50 crore. Shares rose 1.12% amid positive trading volume. The company also announced participation in upcoming investor conferences, reflecting its commitment to investor relations.Dr Reddy's Receives USFDA Observations for API Facility - 17 May, 2025
Dr Reddy's Laboratories announced that its New York API facility received a Form 483 with two observations from the USFDA following a GMP inspection conducted from May 12-16, 2025. The company plans to address these observations within the stipulated timeline.Dr Reddy's Shares Decline Amid High Volume - 16 May, 2025
Dr Reddy's Laboratories shares fell 0.67% to Rs 1228.00 with high trading volume. Despite consistent revenue and profit growth, market sentiment remains bearish.Dr. Reddy's Laboratories Financial Performance Overview - 15 May, 2025
Dr. Reddy's Laboratories reported significant growth in revenue and net profit from March 2021 to March 2025, with EPS increasing notably. The company maintains a low debt-to-equity ratio, indicating financial stability.
Insights on Dr Reddys Laboratories Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTPrice Rise
In the last 7 days, DRREDDY stock has moved up by 3.3%
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 5 quarters, 7.31K Cr → 9.05K Cr (in ₹), with an average increase of 5.2% per quarter
- POSITIVE IMPACT
MF Holding Up
Mutual Funds have increased holdings from 11.14% to 12.89% in Mar 2025 quarter
- POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 3 quarters, 1.25K Cr → 1.59K Cr (in ₹), with an average increase of 11.2% per quarter
NO EFFECTPromoter Holding Unchanged
Promoters holdings remained unchanged at 26.64% of holdings in Mar 2025 quarter
NEGATIVE IMPACTFII Holding Down
Foreign Institutions have decreased holdings from 26.85% to 25.75% in Mar 2025 quarter
- NEGATIVE IMPACT
Retail Holding Down
Retail Investor have decreased holdings from 10.22% to 10.15% in Mar 2025 quarter
About Dr Reddy's Laboratories
Dr Reddy's Laboratories Ltd has a diverse portfolio of products and services, including prescription drugs, generic drugs, over-the-counter drugs, active pharmaceutical ingredients, biotechnology products, and nutraceuticals. Its most popular products include antibiotics, anti-infectives, anti-diabetics, anti-cancer, cardiovascular, gastrointestinal, and dermatology products. Some of its popular brands include Omez, Ciprocin, and Revital. It also has a strong presence in the generics market with its brands such as Reditux and Reditux-D.
Revenue: ₹8,506.00Cr as on March 2025 (Q4 FY25)
Net Profit: ₹1,586.70Cr as on March 2025 (Q4 FY25)
Listing date: 03 Nov, 1994
Chairperson Name: K Satish Reddy
| Organisation | Dr Reddys Laboratories Ltd |
| Headquarters | Hyderabad |
| Industry | Pharmaceuticals |
| CEO | K Satish Reddy |
| E-voting on shares | Click here to vote |
Mutual Funds that own Dr Reddy's Laboratories
Check out the Mutual Funds with significant holdings in Dr Reddy's Laboratories.
FAQs
What is Dr Reddy's Laboratories share price today?
Dr Reddy's Laboratories share price today stands at ₹1362.5, Open: ₹1355, Previous Close: ₹1362.7, High: ₹1366.8, Low: ₹1345, 52 Week High: ₹1421.49, 52 Week Low: ₹1020.
What is today's traded volume of Dr Reddy's Laboratories?
Today's traded volume of Dr Reddy's Laboratories is 14.20L. Which means that 14.20L shares of Dr Reddy's Laboratories were bought and sold on the stock market during today's trading session.
What is Dr Reddy's Laboratories's market cap today?
Today's market capitalisation of Dr Reddy's Laboratories is ₹1,13,702.42 Cr. Market cap or market capitalisation is the total value of a company’s outstanding shares in the stock market, calculated by multiplying the current share price by the total number of shares issued by the company.
What is the 52 week high and 52 week low range of Dr Reddy's Laboratories?
Dr Reddy's Laboratories’s 52 week high is ₹1421.49 and 52 week low is ₹1020. The current share price of Dr Reddy's Laboratories is ₹1362.5, which is -4.15% down from its 52 week high and 33.58% up from its 52 week low.